The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Sanofi
Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis.
 
E. Bridget Kim
No Relationships to Disclose
 
Jack Malespini
No Relationships to Disclose
 
Matthew Lei
Consulting or Advisory Role - AstraZeneca; BTG; Genentech; Genmab; TScan Therapeutics
 
Andrew Robert Branagan
Consulting or Advisory Role - Adaptive Biotechnologies; BeiGene; CSL Behring; Genzyme; Karyopharm Therapeutics; Pharmacyclics/Janssen
 
Diana Cirstea
No Relationships to Disclose
 
Samuel S Han
No Relationships to Disclose
 
Cole W Minsky
No Relationships to Disclose
 
Noopur S. Raje
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Immuneel Therapeutics; Janssen Oncology; Merck; Pfizer; Takeda
Research Funding - Bluebird Bio (Inst)
 
Andrew J Yee
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Oncopeptides; Pfizer; Prothena; Regeneron; Sanofi; Sebia
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Johnson & Johnson/Janssen (Inst); Takeda (Inst)